Business
ViaDerma, Inc. Looks to have Sales Representatives Selling its FDA Registered Medication VitaStem to a Network of 1000 Physician Offices Nationwide in 2018
ViaDerma, Inc. Looks to have Sales Representatives Selling its FDA Registered Medication VitaStem to a Network of 1000 Physician Offices Nationwide in 2018.
About this update from Viaderma, Inc.
[{"type":"text","content":"\nViaDerma, Inc. Looks to have Sales Representatives Selling its FDA Registered Medication VitaStem to a Network of 1000 Physician Offices Nationwide in 2018\n\nViaDerma, Inc. Looks to have Sales Representatives Selling its FDA Registered Medication VitaStem to a Network of 1000 Physician Offices Nationwide in 2018\n\n LOS ANGELES, CA--(Marketwired - December 07, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has begun sales and distribution of its highly anticipated topical antibiotic ointment Vitastem. ViaDerma will work with a new sales and marketing group to put 25 sales representatives on the ground selling ViaDerma's products to networks of Hospitals and directly to physicians' offices. The projected revenues for 2018 from this initiative should generate $6.9 million dollars. The Company has a new distributor in the Philippines, whereby ViaDerma and Biogenx have agreed in principle to terms to distribute VitaStem in the Philippines. The Agreement calls for purchase minimums of 42,500 units the first year, 75,000 the 2nd year, and 125,000 units the 3rd year. The Company expects to ramp up production, monthly as interest in the product continues to grow. ViaDerma estimates they could ramp up production to 75,000 units per month over the next few years.ViaDerma also believes sales in Japan will start soon with an initial demand for approximately 10,000 units of VitaStem per month. Conservatively the Company is projecting initial revenues from Japan of over $2 million dollars per year for 2018. ViaDerma President, D. Christopher Otiko will travel to Japan in January 2018 to meet with distributors and physicians who will be dispensing Vitastem to their patients. Its marketing, sales and distribution partner, Biogenx, Inc. has been preselling the product, under the name of VitaStemtm. Which now retails for $79 and can be purchased online at www.Biogenx.net. The Company plans to start manufacturing the second production run of the product and now has streamlined the manufacturing. The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijua...